Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia

Clinical Cancer Research

Volumn 23, Issue 9, 2017, Pages 2289-2300

  Ben Batalla, Isabel ^a   Erdmann, Robert ^a   Jørgensen, Heather ^b   Mitchell, Rebecca ^b   Ernst, Thomas ^c   Von Amsberg, Gunhild ^a   Schafhausen, Philippe ^a   Velthaus, Janna L ^a   Rankin, Stephen ^b   Clark, Richard E ^d   Koschmieder, Steffen ^e   Schultze, Alexander ^a   Mitra, Subir ^f   Vandenberghe, Peter ^g   Brümmendorf, Tim H ^e   Carmeliet, Peter ^h,i   Hochhaus, Andreas ^c   Pantel, Klaus ^a   Bokemeyer, Carsten ^a   Helgason, G Vignir ^j   Holyoake, Tessa L ^b   Loges, Sonja ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f MILTON KEYNES UNIVERSITY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AXL PROTEIN; BCR ABL PROTEIN; BGB 324; CD34 ANTIGEN; IMATINIB; NILOTINIB; PLACEBO; PONATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; FUSED ALICYCLIC AROMATIC COMPOUND; IMIDAZOLE DERIVATIVE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; R428 COMPOUND; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; K-562 CELL LINE; MOLECULAR LIBRARY; MUTATION; PATHOLOGY;

ANIMALS; APOPTOSIS; BENZOCYCLOHEPTENES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; IMIDAZOLES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIDAZINES; RECEPTOR PROTEIN-TYROSINE KINASES; SMALL MOLECULE LIBRARIES; TRIAZOLES;

EID: 85018412837     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1930     Document Type: Article

References (50)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
2. Groffen J, Stephenson JR,HeisterkampN, de Klein A, Bartram CR,Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
3. Lugo TG, Pendergast AM, Muller AJ,WitteON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247: 1079-82.
4. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189-218.
5. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
6. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
7. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.
8. Jabbour E, Kantarjian H, Cortes J. Use of second-and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015;15: 323-34.
9. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
10. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can preexist to the onset of treatment. Blood 2002;100:1014-8.
11. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
12. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;125:901-6.
13. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25:201-10.
14. Rea D GJ, Guilhot F, Huguet F, Nicolini FE, Legros L, Charbonnier A, et al. Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of The STIM1 Study. Blood 2013;122:515-22.
15. Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 2013;169:1693-707.
16. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 2012;13:927-38.
17. Saussele S, Lauseker M, GratwohlA, BeelenDW,Bunjes D, Schwerdtfeger R, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880-5.
18. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009;8:1924-33.
19. Gamas P, Marchetti S, Puissant A, Grosso S, Jacquel A, Colosetti P, et al. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Leukemia 2009;23:1500-6.
20. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary humanmyeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-31.
21. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, et al. Structural basis for Gas6-Axl signalling. EMBO J 2006;25:80-7.
22. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996; 271:30022-7.
23. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014;14:769-85.
24. Schmidt T, Ben-Batalla I, Schultze A, Loges S. Macrophage-tumor crosstalk: role ofTAMRtyrosine kinase receptors and of their ligands.Cell Mol Life Sci 2012;69:1391-414.
25. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-19.
26. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, et al. AXL mediates resistance to cetuximab therapy. Cancer Res 2014;74: 5152-64.
27. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemiamediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 2013;122:2443-52.
28. Loges S, Gjertsen TJ, Heuser M, Ben-Batalla I, Micklem D, Jorg C, et al. A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS. J Clin Oncol 34, 2016 (suppl; abstr 2561).
29. Wnuk-Lipinska K, Tiron C, Gausdal G, Sandal T, Frink R, Hinz S, et al. BGB324, a selective small molecule Axl kinase inhibitor to overcome EMTassociated drug resistance in carcinomas: therapeutic rationale and early clinical studies. In: Proceedings of the AACR AnnualMeeting; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr 1747.
30. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 2011;118:2211-21.
31. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2011;2:874-85.
32. Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO, et al. Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest 2010; 120:4289-302.
33. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70:1544-54.
34. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.
35. Helgason GV, Allan EK, Mariani S, Mukhopadhyay A, Karvela A, Galavotti S, et al. Inhibition of autophagy in combination with ponatinib or dual PI3K/mTOR inhibition to improve treatment response for both Bcr-Abl dependent and independent mechanisms of TKI-resistance in CML. Blood 2012;120:1664.
36. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
37. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96.
38. Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. How we will treat chronic myeloid leukemia in 2016. Blood Rev 2015;29:137-42.
39. Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharmacother 2013;14:2005-10.
40. Turkina AG, Chelysheva EY, Shuvaev V, Gusarova G, Bykova A, Lazareva OV, et al. Treatment cessation in chronic myeloid leukemia as a part of treatment process: toxicity determined and active stop of tyrosine kinase inhibitors. Blood 2014;124:5518.
41. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.
42. Pegoraro L, Matera L, Ritz J, Levis A, Palumbo A, Biagini G. Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst 1983;70:447-53.
43. Erdmann R JH, Ben-Batalla I, Kruse N, Micklem D, Von Amsberg G, Schafhausen P, et al. BGB324 represents an Axl and BCR-ABL1 inhibitor with activity in the T315I mutant. Blood 2014;124:4512.
44. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005;12:621-37.
45. Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol 2009;2:131-51.
46. Wylie A, Schoepfer J, Berellini G, Cai H, Caravatti G, Cotesta S, et al.. ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood 2014;124:398.
47. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
48. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe precapillary pulmonary hypertension? BMC Pulm Med 2011;11:30.
49. Rios MB, Ault P. Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Clin J Oncol Nurs 2011;15:660-7.
50. Feneyrolles C, Spenlinhauer A, Guiet L, Fauvel B, Dayde-Cazals B, Warnault P, et al. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol Cancer Ther 2014;13:2141-8.